Worth Asset Management LLC Takes $1.35 Million Position in Boston Scientific Co. (NYSE:BSX)

Worth Asset Management LLC acquired a new position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 13,341 shares of the medical equipment provider's stock, valued at approximately $1,346,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its holdings in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new position in shares of Boston Scientific during the 4th quarter worth approximately $33,074,000. Waldron Private Wealth LLC boosted its stake in shares of Boston Scientific by 100.8% in the fourth quarter. Waldron Private Wealth LLC now owns 10,238 shares of the medical equipment provider's stock valued at $914,000 after buying an additional 5,140 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Boston Scientific during the fourth quarter worth $1,174,000. Finally, Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Boston Scientific by 5.6% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 44,233 shares of the medical equipment provider's stock valued at $3,951,000 after purchasing an additional 2,348 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Down 1.0%

Boston Scientific stock traded down $1.01 during trading on Tuesday, reaching $103.16. 8,429,770 shares of the company's stock were exchanged, compared to its average volume of 6,420,046. Boston Scientific Co. has a 52-week low of $71.88 and a 52-week high of $107.17. The firm has a market cap of $152.62 billion, a price-to-earnings ratio of 82.53, a PEG ratio of 2.79 and a beta of 0.68. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The company's 50-day moving average is $100.33 and its two-hundred day moving average is $98.14.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company's revenue was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.56 earnings per share. On average, analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BSX shares. Royal Bank of Canada lifted their price objective on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Needham & Company LLC reissued a "buy" rating and set a $115.00 price objective on shares of Boston Scientific in a research note on Wednesday, May 28th. Evercore ISI increased their target price on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. BTIG Research reissued a "buy" rating and issued a $124.00 price target on shares of Boston Scientific in a report on Wednesday, April 23rd. Finally, Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. Twenty-one research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $116.00.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,572 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the sale, the executive vice president now owns 18,705 shares in the company, valued at $1,955,420.70. This trade represents a 19.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,314 shares of Boston Scientific stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the sale, the executive vice president now owns 22,235 shares of the company's stock, valued at approximately $2,269,304.10. This trade represents a 43.78% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 191,155 shares of company stock valued at $19,556,047. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.